LARIMAR THERAPEUTICS, INC. Peo Total Comp Amt
LARIMAR THERAPEUTICS, INC. (LRMR) reported Peo Total Comp Amt of $3.53 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-20.
Financial Statements › Notes
ecd:PeoTotalCompAmt · last filed 2026-04-20
| Period end | Peo Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $3.53M DEF 14A · filed 2026-04-20 |
| 2024-12-31 | $2.51M DEF 14A · filed 2026-04-20 |
| 2023-12-31 | $3.14M DEF 14A · filed 2026-04-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |